Advanced

Unhealthy marketing of pharmaceutical products: An international public health concern

Mulinari, Shai LU (2016) In Journal of Public Health Policy 37(2). p.149-159
Abstract
I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need... (More)
I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need for additional and more profound reforms to ensure that information about medicines supports quality and resource-efficient care. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Public Health Policy
volume
37
issue
2
pages
149 - 159
publisher
Palgrave Macmillan
external identifiers
  • pmid:26911654
  • scopus:84978780339
ISSN
0197-5897
DOI
10.1057/jphp.2016.6
language
English
LU publication?
yes
id
65300c30-756b-4a31-8ca9-2b9c3e52a661 (old id 8601255)
date added to LUP
2016-02-26 15:32:35
date last changed
2017-10-29 03:23:12
@article{65300c30-756b-4a31-8ca9-2b9c3e52a661,
  abstract     = {I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need for additional and more profound reforms to ensure that information about medicines supports quality and resource-efficient care.},
  author       = {Mulinari, Shai},
  issn         = {0197-5897},
  language     = {eng},
  month        = {02},
  number       = {2},
  pages        = {149--159},
  publisher    = {Palgrave Macmillan},
  series       = {Journal of Public Health Policy},
  title        = {Unhealthy marketing of pharmaceutical products: An international public health concern},
  url          = {http://dx.doi.org/10.1057/jphp.2016.6},
  volume       = {37},
  year         = {2016},
}